BackSAB Biotherapeutics- Warrants (25/07/2027) Overview

SAB Biotherapeutics- Warrants (25/07/2027) Total Liabilities

Latest total liabilities for SABSW: $23M.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$23.43M
↑ 29.33% YoYΔ $5.31M vs prior year quarter

Peer average

Loading

SAB Biotherapeutics- Warrants (25/07/2027) Total Liabilities History

Loading

SAB Biotherapeutics- Warrants (25/07/2027) vs. peers: Total Liabilities Comparison

Loading

SAB Biotherapeutics- Warrants (25/07/2027) Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

SAB Biotherapeutics- Warrants (25/07/2027) (SABSW) FAQ

As of the most recent data (June 2026), SABSW shows a total liabilities of $23M. That compares with $18M in the prior-year period — up 29.3% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, SABSW's total liabilities is now $23M (was $18M) — a 29.3% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether SAB Biotherapeutics- Warrants (25/07/2027) is outperforming or lagging.

Tracking SABSW's total liabilities over time shows whether SAB Biotherapeutics- Warrants (25/07/2027) is scaling, shrinking, or reshaping that part of the business. The current reading is $23M That compares with $18M in the prior-year period — up 29.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total liabilities page, Stockcircle has SAB Biotherapeutics- Warrants (25/07/2027)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total liabilities (currently $23M) with ownership activity and broader fundamentals.